Vanrafia (atrasentan) / Chinook Therap, AbbVie, Novartis  >>  Phase 2
Welcome,         Profile    Billing    Logout  

13 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vanrafia (atrasentan) / Novartis
NCT01424319: Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan

Checkmark Chronic kidney disease
May 2013 - May 2013: Chronic kidney disease
Completed
2b
58
Japan
Atrasentan low dose group, Atrasentan high dose group, Atrasentan placebo group
AbbVie (prior sponsor, Abbott)
Chronic Kidney Disease, Diabetic Nephropathy
07/12
07/12
NCT01356849: Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor

Checkmark P2 data: WCN 2015
Mar 2015 - Mar 2015: P2 data: WCN 2015
Checkmark P2 data: WCN 2015
Mar 2015 - Mar 2015: P2 data: WCN 2015
Checkmark P2 data: WCN 2015
More
Completed
2b
149
US, Canada, RoW
Atrasentan, ABT-627, Placebo
AbbVie (prior sponsor, Abbott)
Chronic Kidney Disease, Diabetic Nephropathy
08/12
08/12
NCT01399580: A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy

Completed
2b
48
US
Atrasentan, ABT-627, Placebo
AbbVie (prior sponsor, Abbott)
Chronic Kidney Disease, Diabetic Nephropathy
09/12
09/12
NCT00920764: A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors

Checkmark Data
Mar 2011 - Mar 2011: Data
Completed
2a
92
US
Placebo for Atrasentan 0.2 mg/mL solution, 0.25 mg Atrasentan QD, 0.75 mg Atrasentan QD, 1.75 mg Atrasentan QD
AbbVie (prior sponsor, Abbott)
Chronic Kidney Disease, Diabetic Nephropathy
04/10
05/10
NCT00039429: Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer

Completed
2
180
US
atrasentan hydrochloride
Eastern Cooperative Oncology Group, National Cancer Institute (NCI)
Kidney Cancer
04/06
 
NCT00038662: Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure

Completed
2
200
US, Canada
Atrasentan
Abbott
Prostatic Neoplasms
 
 
NCT00181558: Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone

Completed
2
44
US
Atrasentan, Zoledronic Acid (Zometa)
Massachusetts General Hospital, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Abbott
Prostate Cancer, Adenocarcinoma of the Prostate
12/06
12/06
NCT00653328: Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma

Terminated
2
15
US
atrasentan hydrochloride, ABT-627, Xinlay, doxil, pegylated liposomal doxorubicin hydrochloride (Doxil)
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
03/09
03/09
NCT02118714 / 2016-000722-19: Atrasentan Spermatogenesis and Testicular Function

Completed
2
20
US, Europe
Atrasentan
AbbVie
Nephropathy, Diabetes
04/18
07/18
2020-004176-18: A Phase 2, Open-Label, Basket Study of Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study) Estudio de fase 2, abierto, “en cesta”, de atrasentán en pacientes con enfermedades glomerulares proteinúricas (estudio AFFINITY)

Ongoing
2
80
Europe
atrasentan, [atrasentan], Film-coated tablet
Chinook Therapeutics U.S., Inc., CHINOOK THERAPEUTICS, U.S., Inc, Chinook Therapeutics U.S., Inc.
Proteinuric glomerular diseases, including:Immunoglobulin A nephropathy (IgAN) (with UPCR 0.5 to <1.0 g/g)Focal segmental glomerulosclerosis (FSGS)Alport SyndromeDiabetes kidney disease (DKD) (as add-on to RAS and sodium glucose co-transporter 2 [SGLT2] inhibitors) Enfermedades glomerulares proteinúricas, que incluyen:Nefropatía por inmunoglobulina A (NIgA) (con UPCR de 0,5 a <1,0 g / g)Glomeruloesclerosis focal y segmentaria (GEFS)Síndrome de AlportNefropatía diabética (ND) (como complemento de los inhibidores del cotransportador 2 [SGLT2] de glucosa y sodio RAS), Proteinuric glomerular diseases:Immunoglobulin A nephropathy (IgAN) Focal segmental glomerulosclerosis (FSGS)Alport SyndromeDiabetes kidney disease (DKD) Enfermedades glomerulares proteinúricas:Nefropatía por inmunoglobulina A (NIgA)Glomeruloesclerosis focal y segmentaria (GEFS)Síndrome de AlportNefropatía diabética (ND), Diseases [C] - Immune System Diseases [C20]
 
 
ASSIST, NCT06841094: Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

Active, not recruiting
2
54
Europe, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Novartis Pharmaceuticals
IgA Nephropathy, Immunoglobulin A Nephropathy
10/25
08/26
AFFINITY, NCT04573920: Atrasentan in Patients With Proteinuric Glomerular Diseases

Active, not recruiting
2
103
Europe, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627
Novartis Pharmaceuticals
IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
07/24
10/26
ASSIST, NCT05834738: Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

Active, not recruiting
2
54
Europe, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Novartis Pharmaceuticals
IgA Nephropathy, Immunoglobulin A Nephropathy
10/25
08/26

Download Options